Citation Impact
Citing Papers
Platelet gene expression and function in patients with COVID-19
2020 Standout
PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
2003 StandoutScience
A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia
2018 StandoutNobel
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
2013 StandoutScienceNobel
Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL
2010 StandoutNobel
TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
2011
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
2003 Standout
AML1, the Target of Multiple Chromosomal Translocations in Human Leukemia, Is Essential for Normal Fetal Liver Hematopoiesis
1996 Standout
An activating mutation in the murine erythropoietin receptor induces erythroleukemia in mice: A cytokine receptor superfamily oncogene
1991
Stem cells, cancer, and cancer stem cells
2001 StandoutNature
Are myelodysplastic syndromes “cancer”?
2006
Leukemia and the disruption of normal hematopoiesis
1991
Oncogenic kinase signalling
2001 StandoutNature
Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL
1997
Role of platelet-derived growth factors in physiology and medicine
2008 Standout
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
1994 StandoutNature
Molecular characterisation of soft tissue tumours: a gene expression study
2002 Standout
ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia
2010
Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1
1994
Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes
1998
Heterogeneity of lineage involvement by trisomy 8 in myelodysplastic syndrome
1995
Soft-Tissue Sarcomas in Adults
2005 Standout
The G Protein-coupled Receptor CL1 Interacts Directly with Proteins of the Shank Family
2000 StandoutNobel
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
2004 Standout
IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis
2010
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
2013 StandoutNobel
Fibroblast growth factor signalling: from development to cancer
2010 Standout
PU.1 and Interferon Consensus Sequence-binding Protein Regulate the Myeloid Expression of the Human Toll-like Receptor 4 Gene
2000 StandoutNobel
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
2005 Standout
The essence of senescence: Figure 1.
2010 Standout
Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a
1997 Standout
Mechanisms and functions of eph and ephrin signalling
2002 Standout
Molecular biology of erythropoietin
1993 StandoutNobel
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
2011 Standout
c-Kit Point mutation in patients with myeloproliferative disorders
1997
A novel gene, MDS2, is fused to ETV6/TEL in a t(1;12)(p36.1;p13) in a patient with myelodysplastic syndrome
2002
Disabling Abl—Perspectives on Abl kinase regulation and cancer therapeutics
2002
The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA
2002
Protein tyrosine kinases and cancer
1997
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
2002 Standout
Configuration of the TP53 Gene as an Independent Prognostic Parameter of Myelodysplastic Syndrome
2003
Genetics of therapy-related myelodysplasia and acute myeloid leukemia
2008
Specificity and mechanism of action of some commonly used protein kinase inhibitors
2000 Standout
Targeting Immunosupportive Cancer Therapies: Accentuate the Positive, Eliminate the Negative
2007 StandoutNobel
Cytokine Signaling in 2002
2002 Standout
Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1α
1998 StandoutNobel
p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)
2014
Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase
2003 Standout
International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome
2001
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
2005 Standout
Sequence and structure-based prediction of eukaryotic protein phosphorylation sites
1999 Standout
Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring
1999 StandoutScience
Posttranslational modification of TEL and TEL/AML1 by SUMO-1 and cell-cycle-dependent assembly into nuclear bodies
2000
Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS- derived leukemia
1993
Tyrosine Kinases as Targets for Cancer Therapy
2005
Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal.
1998 Standout
Proliferation of multipotent hematopoietic cells controlled by a truncated erythropoietin receptor transgene.
1996 StandoutNobel
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
2009 Standout
Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues.
1993
Biology of Gastrointestinal Stromal Tumors
2004 Standout
The macrophage transcription factor PU.1 directs tissue-specific expression of the macrophage colony-stimulating factor receptor.
1994
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies
2004
Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors
1998 StandoutScience
Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML
2004
Oligomeric Structure of the Human EphB2 Receptor SAM Domain
1999 Science
Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines
1995
TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia
1996
The molecular biology of chronic myeloid leukemia
2000
Noxa, a BH3-Only Member of the Bcl-2 Family and Candidate Mediator of p53-Induced Apoptosis
2000 StandoutScience
The t(1;12)(q21;p13) translocation of human acute myeloblastic leukemia results in a TEL-ARNT fusion
2000
The TEL/platelet-derived growth factor β receptor (PDGFβR) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGFβR kinase-dependent signaling pathways
1996
Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays
1998 Standout
Hematopoietic growth factors and their receptors in acute leukemia
1993
Growth Factors and Cancer
1991 StandoutScience
TEL-JAK2 transgenic mice develop T-cell leukemia
2000
Fusion of TEL, the ETS-Variant Gene 6 (ETV6), to the Receptor-Associated Kinase JAK2 as a Result of t(9; 12) in a Lymphoid and t(9; 15; 12) in a Myeloid Leukemia
1997
High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia
1995
The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products.
1996
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
2015 Standout
Protein Modification by SUMO
2004 Standout
CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion Proteins
1997
Comparative Analysis of Mutant Tyrosine Kinase Chemical Rescue
2009 StandoutNobel
Socs-1 Inhibits TEL-JAK2-Mediated Transformation of Hematopoietic Cells through Inhibition of JAK2 Kinase Activity and Induction of Proteasome-Mediated Degradation
2001
High rate of CAD gene amplification in human cells deficient in MLH1 or MSH6
2001 StandoutNobel
CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion Proteins
1997
c-Abl Regulates p53 Levels under Normal and Stress Conditions by Preventing Its Nuclear Export and Ubiquitination
2001 StandoutNobel
ARG tyrosine kinase activity is inhibited by STI571
2001
Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation.
2001
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
Markedly Reduced Expression of Platelet c-mpl Receptor in Essential Thrombocythemia
1997
Mechanism of Action and In Vivo Role of Platelet-Derived Growth Factor
1999 Standout
TEL-JAK2 transgenic mice develop T-cell leukemia
2000
TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities
1995
Works of S. Ridge being referenced
RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up
1998
Genetic lesions in preleukemia.
1992
The novel activation of ABL by fusion to an ets-related gene, TEL.
1995
FMS mutations in myelodysplastic, leukemic, and normal subjects.
1990